Form 4: Liquidia Corp Chief Commercial Officer Reports RSU Vesting and Tax-Related Stock Sale

Liquidia Corp's Chief Commercial Officer, Scott Moomaw, reported the vesting of 1,875 restricted stock units and the subsequent sale of 581 shares to cover tax obligations.

Summary

• Scott Moomaw, Chief Commercial Officer of Liquidia Corp (LQDA), reported changes in his beneficial ownership of company securities.
• On May 30, 2025, 1,875 restricted stock units (RSUs) vested, converting into common stock. These RSUs were part of a 30,000 RSU grant from January 16, 2022, with a total of 24,375 RSUs having vested through this date.
• Following the vesting, on June 2, 2025, Mr. Moomaw sold 581 shares of Liquidia Corp common stock at a price of $16.74 per share.
• This sale was conducted to cover tax liabilities associated with the RSU settlement and was executed under a pre-arranged Rule 10b5-1 plan adopted on June 13, 2022.
• After these transactions, Mr. Moomaw's direct beneficial ownership of common stock stands at 216,038 shares.
• His total holdings also include 36,458 unvested RSUs from a January 11, 2023 grant, 34,184 unvested RSUs from a January 11, 2024 grant, 69,729 unvested RSUs from a January 11, 2025 grant, and 11,002 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there's a sale of shares, it's for tax purposes, which is a routine and expected event for RSU vesting. The vesting itself is a positive for the executive, indicating continued equity alignment. No negative discretionary selling is indicated.

Positives

• The vesting of Restricted Stock Units (RSUs) indicates the achievement of performance or time-based milestones by the executive, aligning their interests with shareholders.
• The sale of shares was explicitly stated to cover tax obligations associated with RSU settlement, which is a common and expected practice for equity compensation.
• The transaction was conducted under a pre-arranged Rule 10b5-1 plan, demonstrating a planned and transparent approach to stock transactions by the insider.

Negatives

• The sale of 581 shares, even if for tax purposes, represents a reduction in the executive's direct common stock holdings.

Future Outlook

This Form 4 primarily reports past transactions and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook. It only details future vesting schedules for existing RSU grants.

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape. It reflects standard executive compensation practices within the pharmaceutical or biotechnology sector, where equity grants like RSUs are common.

Comparison to Industry Standards

• The reported transactions, specifically the vesting of RSUs and subsequent sale to cover taxes, are standard practices for executive compensation in publicly traded companies, particularly in the biotechnology and pharmaceutical industries. Companies like Biogen, Gilead Sciences, or Amgen often use similar equity compensation structures for their executives.
• The use of a Rule 10b5-1 plan for the sale is also a common and recommended practice for insiders to avoid accusations of trading on material non-public information, aligning with best corporate governance practices.

Stakeholder Impact

• Shareholders: The sale of a small number of shares by an executive for tax purposes is a routine event and typically has minimal direct impact on share price or long-term shareholder value. The executive retains a significant equity stake, aligning interests.
• Employees: The RSU vesting and tax-related sale are part of standard executive compensation, which can be seen as a positive for employee morale and retention if compensation structures are perceived as fair and rewarding.

Next Steps

• Continued vesting of remaining unvested RSUs on a quarterly basis for the January 16, 2022 grant.
• Future vesting of RSUs granted on January 11, 2023, January 11, 2024, and January 11, 2025, according to their respective schedules.

Key Dates

Recommendation

Keywords

Liquidia Corp, LQDA, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Sale, Executive Compensation, Scott Moomaw, 10b5-1 Plan